Used in the treatment of autoimmune diseases and transplant rejection due to its ability to selectively target and neutralize the IL-2 receptor alpha (CD25) on activated T cells. By blocking this receptor, it suppresses the overactive immune response, helping to prevent organ rejection in transplant patients and reduce inflammation in autoimmune conditions such as rheumatoid arthritis and multiple sclerosis. It is also being investigated in oncology for its potential to modulate the tumor microenvironment, particularly by depleting regulatory T cells that can hinder anti-tumor immunity. Its high specificity allows for targeted therapy with potentially fewer systemic side effects compared to broad immunosuppressants.